Full Press Release Details
INDIANAPOLIS , July 8, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark from July 12 – 17, 2014. Of particular interest are three oral presentations being highlighted by the Alzheimer's Association via a "reporter tips sheet" or a "featured research session" that may provide important insights to physicians, and increase knowledge through basic research that could inform future clinical research trials:
Lilly will also present a poster, " Delayed-Start Analyses of Solanezumab Phase 3 EXPEDITION Studies in Mild Alzheimer's Disease ," (Poster [P4-172], Wed., July 16 , 11:45 a.m. – 2:15 p.m. CEST ), which will compare effects among delayed-start and early-start treatment groups.
"We are pleased to have a strong scientific presence at this year's AAIC, highlighting our continued commitment to research and sharing key learnings with the Alzheimer's disease community as a whole," said Eric Siemers , M.D., senior medical director of Lilly's Alzheimer's disease team. "The coming together of the scientific community at this meeting is crucial as the prevalence of the disease continues to rise with over 44 million people around the world with dementia, set to reach over 75 million by 2030." 1
Additional data to be presented by Lilly researchers include:
About Alzheimer's Disease Alzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition. 2 It is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. 2 There are currently an estimated 44 million people living with dementia worldwide. 1 The number of people affected by dementia is expected to be more than 75 million in 2030 and 135 million in 2050. 1
About Amyvid (Florbetapir F 18 Injection) 3 Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.
Limitations of Use:
WARNINGS AND PRECAUTIONS
Risk for Image Misinterpretation and Other Errors
MOST COMMON ADVERSE REACTIONS
For more information about Amyvid, please see the Prescribing Information at http://pi.lilly.com/us/amyvid ‐ uspi.pdf .
AM HCP ISI 10JAN2014
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels .
Amyvid™ is a trademark of Eli Lilly and Company.
This press release contains certain forward-looking statements about florbetapir, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaque density in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline, and solanezumab, an agent being investigated as a potential treatment for Alzheimer's disease. This release reflects Lilly's current beliefs; however, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that florbetapir will be commercially successful, that solanezumab will receive regulatory approvals or, if approved, would be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
1 Alzheimer's Disease International. Policy Brief for Heads of Government: The Global Impact of Dementia 2013 - 2050. http://www.alz.co.uk/research/GlobalImpactDementia2013.pdf . Published December 2013 . Accessed on June 4, 2014 . 2 Alzheimer's Association. 2014 Alzheimer's Disease Facts and Figures. http://www.alz.org/downloads/facts_figures_2014.pdf . Accessed on June 4, 2014 . 3 Amyvid [package insert]. Indianapolis, IN : Lilly USA , LLC; 2012.
Refer to: Stefanie Prodouz , +1 (317) 224-5331, [email protected]
SOURCE Eli Lilly and Company